Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head non-human primate comparison against an anti-PD-1 x IL-2α-biased bispecific demonstrates MDNA113’s superior tolerability and significantly wider therapeutic window MDNA113 was well tolerated at doses up to 50 mg/kg in non-human […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.